Coherus BioSciences has announced preliminary results from its Phase I dose-escalation study of CHS-114, an anti-CCR8 antibody, at the 2024 ASCO Annual Meeting. The study demonstrated an acceptable safety profile and no dose-limiting toxicities in heavily pretreated patients with solid tumors. CHS-114 selectively depleted CCR8+ regulatory T cells (Tregs), establishing proof of mechanism and supporting further evaluation in combination with other immuno-oncology agents.
Company Background
Founded in 2010 and headquartered in Redwood City, California, Coherus BioSciences is a commercial-stage biopharmaceutical company specializing in innovative immunotherapies and biosimilars. The company’s mission is to develop and commercialize next-generation cancer treatments to improve patient outcomes through their diversified portfolio of immuno-oncology therapies and FDA-approved biosimilars. Coherus focuses on enhancing the immune system’s ability to fight cancer, with a robust pipeline that includes several promising drug candidates.
Market Focus
Coherus targets the rapidly growing immuno-oncology market, which was valued at approximately $40.74 billion in 2023 and is expected to reach $396.07 billion by 2034, growing at a CAGR of 22.94%. This market expansion is driven by advancements in cancer treatment, the increasing prevalence of cancer, and the growing demand for personalized medicine. Additionally, the biosimilars market, which Coherus is heavily involved in, is projected to reach $70.8 billion by 2025 due to the increasing demand for cost-effective biologic therapies and the expiration of patents on major biologic drugs.
Drugs History
Coherus has developed and commercialized several notable therapies, including:
- LOQTORZI® (toripalimab-tpzi): A next-generation PD-1 inhibitor approved for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC) in combination with chemotherapy or as a single agent.
- UDENYCA® (pegfilgrastim-cbqv): A biosimilar of Neulasta®, used to reduce the risk of infection in patients undergoing chemotherapy.
- CIMERLI® (ranibizumab-eqrn): A biosimilar of Lucentis®, used to treat certain types of macular degeneration.
- YUSIMRY® (adalimumab-aqvh): A biosimilar of Humira®, used to treat various inflammatory conditions.
Recent Developments
Coherus recently presented promising preliminary results from its Phase I dose-escalation study of CHS-114, an anti-CCR8 antibody, at the 2024 ASCO Annual Meeting. The study showed an acceptable safety profile and no dose-limiting toxicities in heavily pretreated patients with solid tumors, supporting further evaluation of CHS-114 in combination with other immuno-oncology agents.
What’s Ahead
Coherus BioSciences continues to make significant strides in the field of immuno-oncology, demonstrating a strong commitment to developing innovative cancer treatments. The company’s strategic focus on next-generation therapies and its robust pipeline position it well to address the growing demand for advanced cancer treatments and biosimilars, enhancing patient outcomes and expanding access to essential medications. Stay tuned for further updates from Coherus and its ongoing clinical trials.
